Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

62.53
Delayed Data
As of Jan 20
 +2.20 / +3.65%
Today’s Change
47.97
Today|||52-Week Range
65.46
+6.22%
Year-to-Date
Better Buy: Merck & Co. Inc. vs. Pfizer
7:12am / MotleyFool.com - Paid Partner Content
Dow 30 Stock Roundup: American Express Buys InAuth, Visa Inks Deal with Wal-Mart
Jan 13 / Zacks.com - Paid Partner Content
US Market Indexes Lower for the Week
Jan 21 / GuruFocus News - Paid Partner Content
Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News
Jan 13 / Zacks.com - Paid Partner Content
5 Drugs That Are Way Cheaper in Canada
Jan 21 / MotleyFool.com - Paid Partner Content
Biotechs stage recovery from Trump line of fire
Jan 12 / FT.com - Paid Partner Content
Liberty Capital Management, Inc. Buys Apple Inc, Alphabet Inc, Celgene Corp, Sells Fo...
Jan 20 / GuruFocus News - Paid Partner Content
2 Upgrades In 1 Day for Merck -- and 3 Things You Need to Know
Jan 12 / MotleyFool.com - Paid Partner Content
Why Bristol-Myers Squibb Co Stock Is Slipping Today
Jan 20 / MotleyFool.com - Paid Partner Content
Company News for January 12, 2017
Jan 12 / Zacks.com - Paid Partner Content
Synergy Pharmaceuticals Consolidating Recent Gains
Jan 20 / TheStreet.com - Paid Partner Content
Trump Attacks Biotech & Pharma: ETFs Bleed
Jan 12 / Zacks.com - Paid Partner Content
Bristol-Myers shares slide on immunotherapy setback
Jan 20 / FT.com - Paid Partner Content
Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo
Jan 12 / Zacks.com - Paid Partner Content
Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy
Jan 20 / Zacks.com - Paid Partner Content
Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again
Jan 12 / Zacks.com - Paid Partner Content
Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?
Jan 20 / Zacks.com - Paid Partner Content
3 Charts Every Bristol-Myers Squibb Shareholder Needs to See
Jan 11 / MotleyFool.com - Paid Partner Content
Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sa...
Jan 20 / TheStreet.com - Paid Partner Content
Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
Jan 11 / Zacks.com - Paid Partner Content
Investors await Trump inauguration; Drugs battle; GE earnings
Jan 20 / CNNMoney.com
Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer
Jan 11 / Zacks.com - Paid Partner Content
BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda
Jan 19 / Zacks.com - Paid Partner Content
Trump faces the press; Rex Tillerson faces the Senate; Pet food takeover
Jan 11 / CNNMoney.com
Bristol-Myers (BMY) Q4 Earnings: Will the Stock Disappoint?
Jan 19 / Zacks.com - Paid Partner Content
Kite Pharma Inks Deals for CAR T Cell Drug in Japan, China
Jan 10 / Zacks.com - Paid Partner Content
How Johnson & Johnson Beat Every Other Big Pharma Stock in 2016
Jan 19 / MotleyFool.com - Paid Partner Content
Roche Gets Priority Review for Immunotherapy Drug Tecentriq
Jan 10 / Zacks.com - Paid Partner Content
Davis R M Inc Buys Oshkosh Corp, American Water Works Co Inc, Thermo Fisher Scientifi...
Jan 18 / GuruFocus News - Paid Partner Content
Incyte/Merck to Start More Epacadostat-Keytruda Studies
Jan 10 / Zacks.com - Paid Partner Content
AstraZeneca Offers Update on Immuno-Oncology Program
Jan 18 / Zacks.com - Paid Partner Content
Incyte's Prospects Get Even Brighter With Merck Announcement
Jan 10 / MotleyFool.com - Paid Partner Content
Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo
Jan 18 / Zacks.com - Paid Partner Content
Stock Research Reports for Wal-Mart, Exxon & Qualcomm
Jan 09 / Zacks.com - Paid Partner Content
Pfizer warns of 'big challenge' ahead from strong dollar
Jan 18 / FT.com - Paid Partner Content
Here's a Biotech IPO You'll Want to Watch
Jan 09 / MotleyFool.com - Paid Partner Content
Why Bristol-Myers Squibb May Be a Merger Target Soon
Jan 17 / TheStreet.com - Paid Partner Content
Eli Lilly's new chief seeks to recover from Alzheimer's drug flop
Jan 05 / FT.com - Paid Partner Content
Cornercap Investment Counsel Inc Buys Activision Blizzard Inc, Apple Inc, TJX Compani...
Jan 17 / GuruFocus News - Paid Partner Content